ApprovedFDA approval

Foundayo (orforglipron)

Eli Lilly (LLY)

Marketer take

An oral, non-peptide GLP-1 for weight management that competes on convenience with injectables like Wegovy and Zepbound and pushes obesity care further into primary care.

Sponsor company
Eli Lilly (LLY)
Indication
To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
Therapeutic area
Obesity, Metabolic
Event
FDA approval
Date
Apr 1, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move